Khan R, et al. - Researchers examined the correlation between payments from the manufacturers of adalimumab and certolizumab to gastroenterologists and Medicare spending on these drugs. For inflammatory bowel disease, biologic medications estimated for the bulk of outpatient treatment expenses. Adalimumab and certolizumab were approved by the US Food and Drug Administration, for Crohn disease (CD) and ulcerative colitis in 2007 and 2012 and for CD in 2006, respectively. Adalimumab and certolizumab were the biologic agents prescribed by the highest number of gastroenterologists for Medicare beneficiaries. Moreover, these gastroenterologists often got payments from the manufacturers of high-revenue medications.